PIM and AKT kinase inhibitors show synergistic cytotoxicity in acute myeloid leukaemia that is associated with convergence on mTOR and MCL1 pathways

British Journal of Haematology

Volumn 167, Issue 1, 2014, Pages 69-79

  Meja, Koremu ^a   Stengel, Chloe ^a   Sellar, Rob ^a   Huszar, Dennis ^b   Davies, Barry R ^b   Gale, Rosemary E ^a   Linch, David C ^a   Khwaja, Asim ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b ASTRAZENECA   (United Kingdom)

Author keywords

Apoptosis; Kinase; Leukaemia; Oncogenes; Therapy

Indexed keywords

4 AMINO N [1 (4 CHLOROPHENYL) 3 HYDROXYPROPYL] 1 (7H PYRROLO[2,3 D]PYRIMIDIN 4 YL) 4 PIPERIDINECARBOXAMIDE; AZD 1897; CD135 ANTIGEN; CD34 ANTIGEN; CD38 ANTIGEN; CYTARABINE; ETOPOSIDE; INITIATION FACTOR 4E BINDING PROTEIN 1; MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN KINASE B INHIBITOR; PROTEIN KINASE PIM 1; PROTEIN KINASE PIM 2; PROTEIN KINASE PIM 3; PROTEIN MCL 1; PROTEIN S6; PROTEIN SERINE THREONINE KINASE; PROTEIN SERINE THREONINE KINASE INHIBITOR; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; MYELOID LEUKEMIA FACTOR 1; PROTEIN KINASE B; PROTEIN KINASE INHIBITOR; PROTO-ONCOGENE PROTEINS PIM; TARGET OF RAPAMYCIN KINASE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL GROWTH; CELL PROLIFERATION; CELL SUBPOPULATION; CELL SURVIVAL; CLINICAL ARTICLE; DRUG CYTOTOXICITY; DRUG POTENTIATION; DRUG TARGETING; ENZYME INHIBITION; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TANDEM REPEAT; ADOLESCENT; ANTAGONISTS AND INHIBITORS; DOSE RESPONSE; DRUG EFFECTS; GENE EXPRESSION; GENETICS; LEUKEMIA, MYELOID, ACUTE; METABOLISM; MIDDLE AGED; MUTATION; TOXICITY; TUMOR CELL LINE; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; GENE EXPRESSION; HUMANS; LEUKEMIA, MYELOID, ACUTE; MIDDLE AGED; MUTATION; MYELOID CELL LEUKEMIA SEQUENCE 1 PROTEIN; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-PIM-1; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES; YOUNG ADULT;

EID: 84909946761     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.13013     Document Type: Article

References (34)

1. Aho, T.L., Sandholm, J., Peltola, K.J., Mankonen, H.P., Lilly, M. & Koskinen, P.J. (2004) Pim-1 kinase promotes inactivation of the pro-apoptotic Bad protein by phosphorylating it on the Ser112 gatekeeper site. FEBS Letters, 571, 43-49.
2. Chen, J., Kobayashi, M., Darmanin, S., Qiao, Y., Gully, C., Zhao, R., Yeung, S.C. & Lee, M.H. (2009) Pim-1 plays a pivotal role in hypoxia-induced chemoresistance. Oncogene, 28, 2581-2592.
3. Chen, L.S., Redkar, S., Taverna, P., Cortes, J.E. & Gandhi, V. (2011) Mechanisms of cytotoxicity to Pim kinase inhibitor, SGI-1776, in acute myeloid leukemia. Blood, 118, 693-702.
4. Chou, T.C. (2010) Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Research, 70, 440-446.
5. Chow, D.C., Wenning, L.A., Miller, W.M. & Papoutsakis, E.T. (2001) Modeling pO(2) distributions in the bone marrow hematopoietic compartment. I. Krogh's model. Biophysical Journal, 81, 675-684.
6. Cuypers, H.T., Selten, G., Quint, W., Zijlstra, M., Maandag, E.R., Boelens, W., van Wezenbeek, P., Melief, C. & Berns, A. (1984) Murine leukemia virus-induced T-cell lymphomagenesis: integration of proviruses in a distinct chromosomal region. Cell, 37, 141-150.
7. Dakin, L.A., Block, M.H., Chen, H., Code, E., Dowling, J.E., Feng, X., Ferguson, A.D., Green, I., Hird, A.W., Howard, T., Keeton, E.K., Lamb, M.L., Lyne, P.D., Pollard, H., Read, J., Wu, A.J., Zhang, T. & Zheng, X. (2012) Discovery of novel benzylidene-1, 3-thiazolidine-2, 4-diones as potent and selective inhibitors of the PIM-1, PIM-2, and PIM-3 protein kinases. Bioorganic & Medicinal Chemistry Letters, 22, 4599-4604.
8. Davies, B.R., Greenwood, H., Dudley, P., Crafter, C., Yu, D.H., Zhang, J., Li, J., Gao, B., Ji, Q., Maynard, J., Ricketts, S.A., Cross, D., Cosulich, S., Chresta, C.C., Page, K., Yates, J., Lane, C., Watson, R., Luke, R., Ogilvie, D. & Pass, M. (2012) Preclinical pharmacology of AZD5363, an inhibitor of AKT: pharmacodynamics, antitumor activity, and correlation of monotherapy activity with genetic background. Molecular Cancer Therapeutics, 11, 873-887.
9. Drygin, D., Haddach, M., Pierre, F. & Ryckman, D.M. (2012) Potential use of selective and nonselective Pim kinase inhibitors for cancer therapy. Journal of Medicinal Chemistry, 55, 8199-8208.
10. Goardon, N., Marchi, E., Atzberger, A., Quek, L., Schuh, A., Soneji, S., Woll, P., Mead, A., Alford, K.A., Rout, R., Chaudhury, S., Gilkes, A., Knapper, S., Beldjord, K., Begum, S., Rose, S., Geddes, N., Griffiths, M., Standen, G., Sternberg, A., Cavenagh, J., Hunter, H., Bowen, D., Killick, S., Robinson, L., Price, A., Macintyre, E., Virgo, P., Burnett, A., Craddock, C., Enver, T., Jacobsen, S.E., Porcher, C. & Vyas, P. (2011) Coexistence of LMPP-like and GMP-like leukemia stem cells in acute myeloid leukemia. Cancer Cell, 19, 138-152.
11. Goldberg, L., Tijssen, M.R., Birger, Y., Hannah, R.L., Kinston, S.J., Schutte, J., Beck, D., Knezevic, K., Schiby, G., Jacob-Hirsch, J., Biran, A., Kloog, Y., Marcucci, G., Bloomfield, C.D., Aplan, P.D., Pimanda, J.E., Gottgens, B. & Izraeli, S. (2013) Genome-scale expression and transcription factor binding profiles reveal therapeutic targets in transgenic ERG myeloid leukemia. Blood, 122, 2694-2703.
12. Gores, G.J. & Kaufmann, S.H. (2012) Selectively targeting Mcl-1 for the treatment of acute myelogenous leukemia and solid tumors. Genes & Development, 26, 305-311.
13. Grandage, V.L., Gale, R.E., Linch, D.C. & Khwaja, A. (2005) PI3-kinase/Akt is constitutively active in primary acute myeloid leukaemia cells and regulates survival and chemoresistance via NF-kappaB, Mapkinase and p53 pathways. Leukemia, 19, 586-594.
14. Hammerman, P.S., Fox, C.J., Birnbaum, M.J. & Thompson, C.B. (2005) Pim and Akt oncogenes are independent regulators of hematopoietic cell growth and survival. Blood, 105, 4477-4483.
15. Hospital, M.A., Green, A.S., Lacombe, C., Mayeux, P., Bouscary, D. & Tamburini, J. (2012) The FLT3 and Pim kinases inhibitor SGI-1776 preferentially target FLT3-ITD AML cells. Blood, 119, 1791-1792.
16. Keeton, E.K., McEachern, K., Dillman, K.S., Palakurthi, S., Cao, Y., Grondine, M.R., Kaur, S., Wang, S., Chen, Y., Wu, A., Shen, M., Gibbons, F.D., Lamb, M.L., Zheng, X., Stone, R.M., DeAngelo, D.J., Platanias, L.C., Dakin, L.A., Chen, H., Lyne, P.D. & Huszar, D. (2013) AZD1208, a potent and selective pan-Pim kinase inhibitor, demonstrates efficacy in preclinical models of acute myeloid leukemia. Blood, 123, 905-913.
17. Kim, K.T., Baird, K., Ahn, J.Y., Meltzer, P., Lilly, M., Levis, M. & Small, D. (2005) Pim-1 is up-regulated by constitutively activated FLT3 and plays a role in FLT3-mediated cell survival. Blood, 105, 1759-1767.
18. Laplante, M. & Sabatini, D.M. (2012) mTOR signaling in growth control and disease. Cell, 149, 274-293.
19. Liu, P., Cheng, H., Roberts, T.M. & Zhao, J.J. (2009) Targeting the phosphoinositide 3-kinase pathway in cancer. Nature Reviews Drug Discovery, 8, 627-644.
20. van Lohuizen, M., Verbeek, S., Krimpenfort, P., Domen, J., Saris, C., Radaszkiewicz, T. & Berns, A. (1989) Predisposition to lymphomagenesis in pim-1 transgenic mice: cooperation with c-myc and N-myc in murine leukemia virus-induced tumors. Cell, 56, 673-682.
21. Lu, J., Zavorotinskaya, T., Dai, Y., Niu, X.H., Castillo, J., Sim, J., Yu, J., Wang, Y., Langowski, J.L., Holash, J., Shannon, K. & Garcia, P.D. (2013) Pim2 is required for maintaining multiple myeloma cell growth through modulating TSC2 phosphorylation. Blood, 122, 1610-1620.
22. Meacham, C.E. & Morrison, S.J. (2013) Tumour heterogeneity and cancer cell plasticity. Nature, 501, 328-337.
23. Mizuki, M., Schwable, J., Steur, C., Choudhary, C., Agrawal, S., Sargin, B., Steffen, B., Matsumura, I., Kanakura, Y., Bohmer, F.D., Muller-Tidow, C., Berdel, W.E. & Serve, H. (2003) Suppression of myeloid transcription factors and induction of STAT response genes by AML-specific Flt3 mutations. Blood, 101, 3164-3173.
24. Narlik-Grassow, M., Blanco-Aparicio, C. & Carnero, A. (2013) The Pim family of serine/threonine kinases in cancer. Medicinal Research Reviews, 34, 136-159.
25. Nawijn, M.C., Alendar, A. & Berns, A. (2011) For better or for worse: the role of Pim oncogenes in tumorigenesis. Nature Reviews Cancer, 11, 23-34.
26. Perciavalle, R.M. & Opferman, J.T. (2013) Delving deeper: MCL-1's contributions to normal and cancer biology. Trends in Cell Biology, 23, 22-29.
27. Quentmeier, H., MacLeod, R.A., Zaborski, M. & Drexler, H.G. (2006) JAK2 V617F tyrosine kinase mutation in cell lines derived from myeloproliferative disorders. Leukemia, 20, 471-476.
28. Reiser-Erkan, C., Erkan, M., Pan, Z., Bekasi, S., Giese, N.A., Streit, S., Michalski, C.W., Friess, H. & Kleeff, J. (2008) Hypoxia-inducible proto-oncogene Pim-1 is a prognostic marker in pancreatic ductal adenocarcinoma. Cancer Biology & Therapy, 7, 1352-1359.
29. Stengel, C., Cheung, C.W., Quinn, J., Yong, K. & Khwaja, A. (2012) Optimal induction of myeloma cell death requires dual blockade of phosphoinositide 3-kinase and mTOR signalling and is determined by translocation subtype. Leukemia, 26, 1761-1770.
30. Walters, D.K., Mercher, T., Gu, T.L., O'Hare, T., Tyner, J.W., Loriaux, M., Goss, V.L., Lee, K.A., Eide, C.A., Wong, M.J., Stoffregen, E.P., McGreevey, L., Nardone, J., Moore, S.A., Crispino, J., Boggon, T.J., Heinrich, M.C., Deininger, M.W., Polakiewicz, R.D., Gilliland, D.G. & Druker, B.J. (2006) Activating alleles of JAK3 in acute megakaryoblastic leukemia. Cancer Cell, 10, 65-75.
31. Xiang, Z., Luo, H., Payton, J.E., Cain, J., Ley, T.J., Opferman, J.T. & Tomasson, M.H. (2010) Mcl1 haploinsufficiency protects mice from Myc-induced acute myeloid leukemia. The Journal of Clinical Investigation, 120, 2109-2118.
32. Yan, B., Zemskova, M., Holder, S., Chin, V., Kraft, A., Koskinen, P.J. & Lilly, M. (2003) The PIM-2 kinase phosphorylates BAD on serine 112 and reverses BAD-induced cell death. Journal of Biological Chemistry, 278, 45358-45367.
33. Zhang, F., Beharry, Z.M., Harris, T.E., Lilly, M.B., Smith, C.D., Mahajan, S. & Kraft, A.S. (2009) PIM1 protein kinase regulates PRAS40 phosphorylation and mTOR activity in FDCP1 cells. Cancer Biology & Therapy, 8, 846-853.
34. Zhao, S., Konopleva, M., Cabreira-Hansen, M., Xie, Z., Hu, W., Milella, M., Estrov, Z., Mills, G.B. & Andreeff, M. (2004) Inhibition of phosphatidylinositol 3-kinase dephosphorylates BAD and promotes apoptosis in myeloid leukemias. Leukemia, 18, 267-275.